Q1 2022 13F Holders as of 3/31/2022
-
Type / Class
-
Equity / Common stock, par value $0.001 per share
-
Shares outstanding
-
5.43M
-
Number of holders
-
38
-
Total 13F shares, excl. options
-
2.42M
-
Shares change
-
-1.19M
-
Total reported value, excl. options
-
$4.5M
-
Value change
-
-$2.77M
-
Put/Call ratio
-
0.02
-
Number of buys
-
15
-
Number of sells
-
-22
-
Price
-
$1.86
Significant Holders of Aprea Therapeutics, Inc. - Common stock, par value $0.001 per share (APRE) as of Q1 2022
50 filings reported holding APRE - Aprea Therapeutics, Inc. - Common stock, par value $0.001 per share as of Q1 2022.
Aprea Therapeutics, Inc. - Common stock, par value $0.001 per share (APRE) has 38 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 2.42M shares
of 5.43M outstanding shares and own 44.5% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (355K shares), KENNEDY CAPITAL MANAGEMENT, INC. (335K shares), RENAISSANCE TECHNOLOGIES LLC (298K shares), MORGAN STANLEY (247K shares), BlackRock Inc. (230K shares), GEODE CAPITAL MANAGEMENT, LLC (150K shares), SUSQUEHANNA INTERNATIONAL GROUP, LLP (111K shares), CITADEL ADVISORS LLC (77.1K shares), BRIDGEWAY CAPITAL MANAGEMENT, LLC (60K shares), and GROUP ONE TRADING, L.P. (53.1K shares).
This table shows the top 38 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.